Lower nitric oxide susceptibility of trivalent antimony-resistant amastigotes of Leishmania infantum

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 10, 2005, Pages 4406-4409

  Holzmuller, P ^a   Sereno, D ^a   Lemesre, J L ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (2 AMINOETHYL) N (2 AMMONIOETHYL)AMINO]DIAZEN 1 IUM 1,2 DITHIOLATE; ANTIMONY; ANTIMONY TARTRATE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; SODIUM NITRITE; UNCLASSIFIED DRUG;

AMASTIGOTE; APOPTOSIS; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG SENSITIVITY; DRUG TARGETING; LEISHMANIA INFANTUM; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMONY POTASSIUM TARTRATE; ANTIPROTOZOAL AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELLS, CULTURED; DRUG RESISTANCE; INHIBITORY CONCENTRATION 50; INTERFERON TYPE II; LEISHMANIA INFANTUM; LIFE CYCLE STAGES; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; NITRIC OXIDE;

EID: 25844467081     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.10.4406-4409.2005     Document Type: Article

References (26)

1. Brochu, C., J. Wang, G. Roy, N. Messier, X. Y. Wang, N. G. Saravia, and M. Ouellette. 2003. Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob. Agents Chemother. 47:3073-3079.
2. Carrio, J., and C. Portus. 2002. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. BMC Pharmacol. 2:11.
3. Carter, K. C., S. Sundar, C. Spickett, O. C. Pereira, and A. B. Mullen. 2003. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob. Agents Chemother. 47:1529-1535.
4. Colasanti, M., L. Gradoni, M. Mattu, T. Persichini, L. Salvati, G. Venturini, and P. Ascenzi. 2002. Molecular bases for the anti-parasitic effect of NO. Int. J. Mol. Med. 9:131-134.
5. Das, L., N. Datta, S. Bandyopadhyay, and P. K. Das. 2001. Successful therapy of lethal murine visceral leishmaniasis with cystatin involves upregulation of nitric oxide and a favorable T cell response. J. Immunol. 166:4020-4028.
6. Dey, S., M. Ouellette, J. Lightbody, B. Papadopoulou, and B. P. Rosen. 1996. An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae. Proc. Natl. Acad. Sci. USA 93:2192-2197.
7. Faraut-Gambarelli, F., R. Piarroux, M. Deniau, B. Giusiano, P. Marty, G. Michel, B. Faugere, and H. Dumon. 1997. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 41:827-830.
8. Frezard, F., C. Demicheli, C. S. Ferreira, and M. A. Costa. 2001. Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrob. Agents Chemother. 45:913-916.
9. Goodwin, L. G. 1995. Pentostam (sodium stibogluconate); a 50-year personal reminiscence. Trans. R. Soc. Trop. Med. Hyg. 89:339-341.
10. Gradoni, L., M. Gramiccia, and A. Scalone. 2003. Visceral leishmaniasis treatment, Italy. Emerg. Infect. Dis. 9:1617-1620.
11. Holzmuller, P., D. Sereno, M. Cavaleyra, I. Mangot, S. Daulouede, P. Vincendeau, and J. L. Lemesre. 2002. Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect. Immun. 70:3727-3735.
12. Lawn, S. D., V. Yardley, F. Vega-Lopez, J. Watson, and D. N. Lockwood. 2003. New World cutaneous leishmaniasis in returned travellers: treatment failures using intravenous sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 97:443-445.
13. Lemesre, J. L., M. P. Blanc, P. Grebaut, V. Zilberfarb, and V. Carrière. 1994. Culture continue des formes amastigotes de leishmanies en condition axénique. Réalisation du cycle évolutif in vitro. Med. Armees 22:99-100.
14. Li, J., S. Sutterwala, and J. P. Farrell. 1997. Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production. Infect. Immun. 65:3225-3230.
15. Marovich, M. A., R. Lira, M. Shepard, G. H. Fuchs, R. Kruetzer, T. B. Nutman, and F. A. Neva. 2001. Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin. Infect. Dis. 33:1076-1079.
16. Mnaimneh, S., M. Geffard, B. Veyret, and P. Vincendeau. 1997. Albumin nitrosylated by activated macrophages possesses antiparasitic effects neutralized by anti-NO-acetylated-cysteine antibodies. J. Immunol. 158:308-314.
17. Mukhopadhyay, R., S. Dey, N. Xu, D. Gage, J. Lightbody, M. Ouellette, and B. P. Rosen. 1996. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc. Natl. Acad. Sci. USA 93:10383-10387.
18. Murray, H. W., and S. Delph-Etienne. 2000. Roles of endogenous gamma interferon and macrophage microhicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68:288-293.
19. Roy, J. B., and R. G. Wilkerson. 1984. Fallibility of Griess (nitrite) test. Urology. 23:270-271.
20. Sereno, D., E. Guilvard, S. Maquaire, M. Cavaleyra, P, Holzmuller, A. Ouaissi, and J. L. Lemesre. 2001. Experimental studies on the evolution of antimony-resistant phenotype during the in vitro life cycle of Leishmania infantum: implications for the spread of chemoresistance in endemic areas. Act. Trop. 80:195-205.
21. Sereno, D., and J. L. Lemesre. 1997. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob. Agents Chemother. 41:972-976.
22. Sereno, D., P. Holzmuller, I. Mangot, G. Cuny, A. Ouaissi, and J. L. Lemesre. 2001. Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob. Agents Chemother. 45:2064-2069.
23. Shaked-Mishan, P., N. Ulrich, M. Ephros, and D. Zilberstein. 2001. Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 276:3971-3976.
24. 2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J. Biol. Chem. 278:25120-25132.
25. Tsuchiya, S., Y. Kobayashi, Y. Goto, H. Okumura, S. Nakae, T. Konno, and K. Tada. 1982. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res. 42:1530-1536.
26. Vouldoukis, I., J. C. Drapier, A. K. Nussler, Y. Tselentis, O. A. Da Silva, M. Gentilini, D. M. Mossalayi, L. Monjour, and B. Dugas. 1996. Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway. Antimicrob. Agents Chemother. 40:253-256.